Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sesen Bio Inc (SESN)

Sesen Bio Inc (SESN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,723
  • Shares Outstanding, K 199,464
  • Annual Sales, $ 26,540 K
  • Annual Income, $ -340 K
  • 60-Month Beta 0.82
  • Price/Sales 3.72
  • Price/Cash Flow 6.19
  • Price/Book 0.69
Trade SESN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings -0.05 on 08/08/22
  • Next Earnings Date 11/14/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 280.33% ( -19.00%)
  • Historical Volatility 132.85%
  • IV Percentile 86%
  • IV Rank 22.01%
  • IV High 974.49% on 09/15/22
  • IV Low 84.39% on 12/23/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 341
  • Volume Avg (30-Day) 927
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 77,828
  • Open Int (30-Day) 75,694

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3650 +37.01%
on 09/27/22
0.6850 -26.99%
on 09/15/22
-0.0999 (-16.65%)
since 09/06/22
3-Month
0.3650 +37.01%
on 09/27/22
0.9650 -48.18%
on 07/14/22
-0.3442 (-40.77%)
since 07/06/22
52-Week
0.3650 +37.01%
on 09/27/22
1.4700 -65.98%
on 10/20/21
-0.2279 (-31.30%)
since 10/06/21

Most Recent Stories

More News
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the...

SNY : 38.90 (-2.31%)
BMRN : 91.48 (+2.18%)
SESN : 0.5001 (+4.21%)
MORF : 30.37 (+5.56%)
SESEN BIO, INC. (SESN) Stock Moves -0.43%: What You Should Know

SESEN BIO, INC. (SESN) closed at $0.39 in the latest trading session, marking a -0.43% move from the prior day.

SESN : 0.5001 (+4.21%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBET, RMED, OCSL, SESN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SBET : 0.8600 (+1.16%)
RMED : 6.78 (+5.12%)
OCSL : 6.21 (-1.58%)
SESN : 0.5001 (+4.21%)
SESEN BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sesen Bio, Inc. - SESN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sesen Bio, Inc. (NasdaqCM: SESN) (the “Company”)...

SESN : 0.5001 (+4.21%)
Wave Therapeutics (WVE) Up on Update From Huntington's Study

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

STSA : 5.57 (+7.53%)
WVE : 3.74 (+2.19%)
SESN : 0.5001 (+4.21%)
ARDS : 1.1400 (-0.87%)
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

AZN : 54.91 (-3.21%)
BMY : 70.24 (-1.69%)
PBYI : 2.52 (+3.28%)
SESN : 0.5001 (+4.21%)
SESN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sesen Bio, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sesen Bio, Inc. (NASDAQ: SESN) and Carisma Therapeutics Inc. is fair to Sesen Bio shareholders. Pre-merger Sesen Bio...

SESN : 0.5001 (+4.21%)
Sesen Bio and Carisma Therapeutics Announce Merger Agreement

Sesen Bio, Inc. (Nasdaq: SESN ) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies,...

SESN : 0.5001 (+4.21%)
SESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know

SESEN BIO, INC. (SESN) closed at $0.67 in the latest trading session, marking a -1.59% move from the prior day.

SESN : 0.5001 (+4.21%)
Intellia (NTLA) Reports Positive Results for CRISPR Candidates

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).

REGN : 731.86 (-1.85%)
NTLA : 62.69 (+2.91%)
SESN : 0.5001 (+4.21%)
ARDS : 1.1400 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven...

See More

Key Turning Points

3rd Resistance Point 0.5853
2nd Resistance Point 0.5396
1st Resistance Point 0.5097
Last Price 0.5001
1st Support Level 0.4341
2nd Support Level 0.3884
3rd Support Level 0.3585

See More

52-Week High 1.4700
Fibonacci 61.8% 1.0479
Fibonacci 50% 0.9175
Fibonacci 38.2% 0.7871
Last Price 0.5001
52-Week Low 0.3650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar